April 15th, 2020 | 08:10 CEST
BioNTech, Evotec, EXMceuticals - Stocks with potential
Table of contents:
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Natural medicine for health
EXMceuticals is a young company focused on the extraction of pure medicinal ingredients from the cannabis plant. The listed company has operations in and near Lisbon, Portugal, and plans to supply the enormous European market with high-quality and pure products from there in the future. In the context of the current Corona Crisis and the time after, the team around CEO Jonathan Summers is an ideal platform to serve a product universe that offers people added value based on entirely natural and under-appreciated ingredients.
EXMceutials already has an operational R&D unit for cannabinoids. It is now in the final stages of finishing the detailed design and equipment specification for an EU-GMP purification facility that is currently unique in Europe in terms of scale. The various fields of use for cannabis in modern medicine will become increasingly important and offer attractive growth prospects for the company and therefore it's investors.
Corona vaccine from 2021
BioNTech has been one of the most discussed companies in connection with the development of a vaccine for the prevention of the spread of Covid-19 for several weeks now. The German company works in cooperation with the pharmaceutical giant Pfizer. The vaccine is expected to be available in a high number of doses in 2021. Pfizer is financing the development of the vaccine and BioNTech will subsequently refund 50% of the costs from the expected revenues. The target markets for the vaccine will be Europe and the USA.
Medical innovation service provider
Evotec is active in the research and development of active ingredients. The main focus is on gene therapy. The company develops new technologies and applies them to access more precise and effective drugs. Evotec cooperates with renowned partners around the globe in early phases to increase efficiency in the development of active ingredients as an external innovation service provider. According to Evotec, quality and speed are at the forefront of its collaboration with customers.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.